Sugi Predict

Sugi Predict / Compounds / SCHEMBL23923715

SCHEMBL23923715

SCHEMBL23923715

COC(=O)c1[nH]c(C)c(S(=O)(=O)Cl)c1C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.45
▸ RAB9A P51151 4/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ HPGD P15428 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ MAPK1 P28482 3/20 0.37
▸ HTT P42858 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16237097 0.85 NPSR1 (0.40) NPSR1RAB9ANPC1CYP1A2CYP2C9
SCHEMBL1437726 0.83 CYP1A2 (0.62) NPSR1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL16236784 0.83 NPSR1 (0.39) NPSR1RAB9ANPC1CYP1A2CYP2C9
SCHEMBL23923607 0.83 NPSR1 (0.45) NPSR1RAB9ANPC1CYP1A2CYP2C9
SCHEMBL25012805 0.77 NPSR1 (0.46) NPSR1RAB9ANPC1CYP1A2CYP2C9
SCHEMBL12531935 0.75 CYP1A2 (0.64) NPSR1RAB9ANPC1CYP1A2CYP2C9
SCHEMBL30483935 0.72 NPSR1 (0.50) NPSR1RAB9ANPC1CYP1A2CYP2C9
SCHEMBL7256405 0.72 NPSR1 (0.79) NPSR1RAB9ANPC1L3MBTL1TSHR
SCHEMBL15330789 0.71 NPSR1 (0.51) NPSR1RAB9ANPC1CYP1A2CYP2C9
SCHEMBL14011276 0.71 NPSR1 (0.50) NPSR1RAB9ANPC1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010912-A Antiviral 1, 3-dioxoindene compounds 诺华股份有限公司 2026-05-12 — — CN disclosed
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-06-12 — — US disclosed
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds NOVARTIS AG (CH) 2025-04-29 — — US disclosed
CN-115867545-A Antiviral 1,3 dioxoindene compounds 诺华股份有限公司 2023-03-28 — — CN disclosed
EP-4139301-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS Novartis AG (CH) 2023-03-01 — — EP disclosed
WO-2021214080-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-28 — — WO disclosed
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-21 — — US disclosed
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 NPSR1 3075/4885RAB9A 1375/4885NPC1 60/4885
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 NPSR1 3075/4885RAB9A 1375/4885NPC1 60/4885
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds IRF3, EIF2AK2, ZC3HAV1 NPSR1 3075/4885RAB9A 1375/4885NPC1 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.